Login     Register  
    Home   |   Search   |   Director's Bio   |   About/Contact Us   |   Disclaimer  
BioEndeavor - Engaged Thinking  
 About BioEndeavor
 Engaged Thinking
 Engaged Thinking Blog
 Engaged Innovation Case Studies
 Engaged Thinking Academy
 Engaged Innovation Directory
 Capacity Development
Neglected Tropical Diseases 
Non-Communicable Diseases 

Drug Discovery 
 Add Organization 

Drug Discovery
GlaxoSmithKline - DNDi CollaborationGo Back  
Organization URL

GlaxoSmithKline - DNDi Collaboration

Year Established: 2008

June 2011, a new two-year collaboration agreement between GlaxoSmithKline (GSK) and Drugs for Neglected Diseases initiative (DNDi) was signed with the objective of identifying a molecule with in vitro and in vivo activities against Visceral leishmaniasis, American trypanosomiasis (Chagas’ disease) or human African trypanosomiasis (HAT). Patients need better treatments urgently as the existent ones are not suitable due to the emergence of parasite resistance, their severe side effects and toxicity, costs or non-suitable routes of administration.

This collaboration focuses on the phenotypic screening of compounds belonging to a specific chemical class or with a putative target based on an “homology/orthology” hypothesis. Identified hit(s) will be studied in the corresponding animal models in order to evaluate their in vivo efficacy. Further progression of efficacious compounds will follow in collaboration with our partner. During 2011, GSK contributed different sets of compounds for testing against T. brucei, T. cruzi and Leishmania at the screening centres provided by DNDi.

Target Sector:
Drug Discovery

Typology of Knowledge Network:
Public-Private Partnership (PPP)

Knowledge Type / Focus:
Biological Materials

Participant Type:
Private Sector

Objective / Knowledge Governance:
Cooperative Research

© 2010-2017 BioEndeavor.Net
Privacy and Security Statement Disclaimer Adding Directory Profiles